Codeine Linctus Reclassified as Prescription-Only Medicine
UK MHRA announces codeine linctus, an oral solution or syrup to treat dry cough, to be reclassified to prescription-only medicine due to risk of abuse and addiction
The UK Medicines and Healthcare products Regulatory Agency (MHRA) announced that codeine linctus, an oral solution or syrup licensed to treat dry cough in adults, is to be reclassified to a prescription-only medicine due to the risk of abuse, dependency and overdose.
About Codeine linctus
Codeine linctus is an opioid medicine which has previously been available to buy in pharmacies under the supervision of a pharmacist but will now only be available on prescription following an assessment by a healthcare professional.
Process Behind Change
• Since 2019, there have been increasing reports in the media of codeine linctus being misused as an ingredient in a recreational drink, commonly referred to as ‘Purple Drank’.
• The decision to reclassify the medicine has been made following a consultation with independent experts, healthcare professionals and patients. 992 responses were received.
• The consultation was launched by the MHRA after Yellow Card reports indicated instances of the medicine being abused, rather than for its intended use as a cough suppressant.
• Responses to the consultation identified the pressure pharmacists were under to provide the medicine to those suffering from addiction.
Words from MHRA Chief
• Dr Alison Cave, MHRA chief safety officer, said: “Patient safety is our top priority. Codeine linctus is an effective medicine for long term dry cough, but as it is an opioid, its misuse and abuse can have major health consequences.
• We would like to thank all the patients, independent experts and health professionals who responded to our consultation.
• As a result, and taking into account the reports we have received in relation to abuse, we have reclassified codeine linctus to a prescription-only medicine for the benefit of patients, carers and healthcare professionals across the UK.
• Codeine addiction can be a gradual process. If you have been taking it for a long time and want to stop, you can talk to your healthcare provider and reduce the amount you take slowly.
• If you feel that you are addicted or have concerns for someone who has been using codeine linctus for too long, you can seek advice on the NHS website. Support groups and self-help groups are also available such as Talk to FRANK.
• We ask people to report any adverse reactions from codeine linctus via the MHRA Yellow Card scheme.”
Alternatives Drugs
Alternative non-prescription cough medicines are available for short-term coughs to sooth an irritated throat, including honey and lemon mixtures and cough suppressants.
Patients are urged to speak to a pharmacist for advice and not to buy codeine linctus from an unregistered website as it could be dangerous.
Words from RPS
• Professor Claire Anderson, president of the Royal Pharmaceutical Society, said: “We welcome the decision to reclassify codeine linctus to a prescription-only medication as a positive step to protect patient safety.
• This decision not only addresses concerns about the misuse and addictive potential of codeine linctus but also underscores the importance of prioritising patient well-being.
• There are many alternative non-codeine-based products available to treat a dry cough. As the most accessible of healthcare professionals, community pharmacists and their teams will continue to provide expert advice on managing dry cough and guide people towards suitable treatments.
Words from PAGB
• Michelle Riddalls, chief executive officer of PAGB, the consumer healthcare association said: “The over-the-counter (OTC) industry takes any issue relating to patient safety very seriously. Following evidence of the recreational use of codeine linctus, and in line with our consultation response, we support the reclassification of codeine linctus to a prescription-only medicine.
• Patient safety and wellbeing is paramount for manufacturers of OTC medicines. Alongside the MHRA, companies that make OTC products in the UK continually monitor the safety of medicines via routine pharmacovigilance measures.
• The decision to reclassify codeine linctus demonstrates that the reclassification system is effective; this will ensure that people are only able to access medicines that allow them to self-care safely.”
Further Updates
The Agency announced that further information is available in the Drug Safety Update. - The brands which will be reclassified are Codeine Linctus BP (LCM Limited, and Pinewood Laboratories Limited), Bells Healthcare Codeine Linctus 15mg/5ml Oral Solution (Bell Sons & Company [Druggists] Limited), Care Codeine 15mg/5ml Oral Solution Sugar Free (Thornton & Ross), Galcodine Linctus (Thornton & Ross) and Pulmo Bailly (Dendron Brands Limited).
About MHRA
The UK Medicines and Healthcare products Regulatory Agency (MHRA) is responsible for regulating all medicines and medical devices in the UK by ensuring they work and are acceptably safe.
Optimize Your trial insights with Clival Database.
Are you exhausted from the uncertainty of trial insights pricing? Clival Database ensures the clarity in the midst of the global scenario for clinical trials to you.Clival Database is one of the best databases that offers an outstanding number of clinical trial data in terms of 50,000+ molecules and from primary regulatory markets as well as new entrants like Indian and Chinese markets.
With Clival, you get accurate positioning of historical sales data, patent database, company profiling, safety & efficacy, and prediction of launch of new innovative molecules helping you to align your research and driving down the cost.
To add value, we further break down our analytics for you so that improving your operational effectiveness; optimizing your clinical trials; and offering you accurate and high-quality data at lowest possible prices becomes possible.
Elevate your trial success rate with the cutting-edge insights from Clival database.
Check it out today and make more informed sourcing decisions! Learn More!
